Onconetix, Inc. (ONCO)
ONCONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.19
+0.1600 (+5.28%) today
Regular session, Nov 13, 3:45 PM ET
- Market cap
- $2.14m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.91 to $3.35
- 52-week range
- $2.94 to $1,610.00
- Average volume
- –
- Previous close
- $3.03
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $304.0k | $304.0k | $21.0k | $17.0k |
| Gross profit | $269.0k | $248.0k | -$2,000 | $4,000 |
| Operating income | -$2.07m | -$1.28m | -$10.23m | -$2.73m |
| Net income | -$8.78m | $5.67m | -$4.21m | -$2.87m |
Last four quarters: revenue $646.0k, margin -1578.3%, free cash flow –
News
8 latest- Stocks Pressured by Rising Bond YieldsBarchart · 3 minutes ago
- NeoVolta Power Signs $116 Mln Master Purchase Agreement RTTNews · 12 minutes ago
- OptimumBank (OPHC) Q3 2026 Earnings Call TranscriptThe Motley Fool · 15 minutes ago
- Why Digital Turbine Stock Plunged This WeekThe Motley Fool · 19 minutes ago
- Celsius vs. Colgate-Palmolive: Which Consumer Goods Stock Is a Better Buy for 2027?The Motley Fool · 21 minutes ago
- Notable Friday Option Activity: KR, MP, SPCXBNK Invest · 22 minutes ago
- Noteworthy Friday Option Activity: ALNY, SMCI, BURLBNK Invest · 22 minutes ago
- Noteworthy Friday Option Activity: APP, CRCL, MRVLBNK Invest · 22 minutes ago
The company
Onconetix (Nasdaq: ONCO) is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ('EU') under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test ('LDT') through its license agreement with Labcorp.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- onconetix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.